

## Review Form 1.7

Journal Name:	<b>Journal of Advances in Medicine and Medical Research</b>
Manuscript Number:	<b>Ms_JAMMR_105092</b>
Title of the Manuscript:	<b>Rhesus Change in Pleomorphic Sarcoma Patients with Chemotherapy Protocol Non Rhabdomyosarcoma Soft Tissue Sarcoma (Nrsts) Cycle 5</b>
Type of the Article	<b>Case Report</b>

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljammr.com/index.php/JAMMR/editorial-policy> )

### **PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</b>
<p><b>Compulsory</b> REVISION comments</p> <p>1. <b>Is the manuscript important for scientific community?</b> (Please write few sentences on this manuscript)</p> <p>2. <b>Is the title of the article suitable?</b> (If not please suggest an alternative title)</p> <p>3. <b>Is the abstract of the article comprehensive?</b></p> <p>4. <b>Are subsections and structure of the manuscript appropriate?</b></p> <p>5. <b>Do you think the manuscript is scientifically correct?</b></p> <p>6. <b>Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form.</b></p> <p><b>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</b></p>	<p><b>Yes, Rhesus Change has been one of the most important chemotherapy-induced side effects. Reporting the related cases can help scientists with elucidating the underlying mechanisms of this phenomenon.</b></p> <p><b>Here is my suggestion:</b> "Chemotherapy-induced rhesus blood group switch in pleomorphic sarcoma patient during Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Chemotherapy protocol, Cycle 5"</p> <p><b>The chemotherapy term is far general, the authors should precisely define the agents that were used through the treatment plan of the patient.</b></p> <p>Yes Yes</p> <p><b>No, the respected authors should review and bring other similar cases, discuss the probable cause and mechanisms.</b></p>	
<p><b>Minor</b> REVISION comments</p> <p>1. <b>Is language/English quality of the article suitable for scholarly communications?</b></p>	<p>No, major revision is needed to correct grammatical errors.</p>	
<p><b>Optional/General</b> comments</p>	<p>Thank you for presenting this interesting case, please provide the proper explanations for the following questions:</p> <ol style="list-style-type: none"> <li>1. When was the diagnosis confirmed and when did the treatment start?</li> <li>2. What was the indication of such blood transfusions?</li> <li>3. Provide the patient treatment plan and chemotherapeutic agents that were applied for him in detail.</li> <li>4. Please include similar cases that resulted in this side effect of chemotherapy, with proper citation in the text.</li> </ol>	

**Review Form 1.7**

**PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

**Reviewer Details:**

Name:	<b>Zahra Malakoutikhah</b>
Department, University & Country	<b>Applied Physiology Research Center, Isfahan University of Medical Sciences, Iran</b>